Interferon Beta Biosimilar Recombinant Protein (IFNAR1) for Research
Pre-Made Interferon Beta Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Interferon beta is a cytokine in the interferon family used to treat multiple sclerosis (MS)
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-873-1mg | 1mg | 3090 |
| GMP-Bios-INN-873-10mg | 10mg | |
| GMP-Bios-INN-873-100mg | 100mg | |
| GMP-Bios-INN-873-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Interferon Beta Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC |
| INN Name | Interferon Beta |
| Target | IFNAR1 |
| Format | Recombinant Protein |
| Derivation | 0 |
| Species Reactivity | human |
| CH1 Isotype | IFNB1 (interferon beta 1, IFNB) *a (C38) 22-187 |
| VD LC | IFNB1 (interferon beta 1, IFNB) *a (C38) 22-187 |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Biogen, Inc. (Cambridge MA USA) / Merck Serono International S.A. (Geneva Switzerland) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - IFNAR1
1. Protein Interferon alpha/beta receptor 1
2. Gene IFNAR1
3. Organism Homo sapiens (Human)
Function
Component of the receptor for type I interferons, including interferons alpha, IFNB1 and IFNW1 (PubMed:2153461, PubMed:7665574, PubMed:10049744, PubMed:14532120, PubMed:15337770, PubMed:21854986).
Functions in general as heterodimer with IFNAR2 (PubMed:7665574, PubMed:10049744, PubMed:21854986).
Type I interferon binding activates the JAK-STAT signaling cascade, and triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and the IFNR alpha- and beta-subunits themselves (PubMed:7665574, PubMed:21854986, PubMed:32972995).
Can form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway (By similarity).

